JP2021525278A5 - - Google Patents

Info

Publication number
JP2021525278A5
JP2021525278A5 JP2021515306A JP2021515306A JP2021525278A5 JP 2021525278 A5 JP2021525278 A5 JP 2021525278A5 JP 2021515306 A JP2021515306 A JP 2021515306A JP 2021515306 A JP2021515306 A JP 2021515306A JP 2021525278 A5 JP2021525278 A5 JP 2021525278A5
Authority
JP
Japan
Prior art keywords
formula
group
optionally substituted
aryl
hydrogen
Prior art date
Application number
JP2021515306A
Other languages
English (en)
Japanese (ja)
Other versions
JP7384903B2 (ja
JP2021525278A (ja
JPWO2019224790A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/054315 external-priority patent/WO2019224790A2/en
Publication of JP2021525278A publication Critical patent/JP2021525278A/ja
Publication of JP2021525278A5 publication Critical patent/JP2021525278A5/ja
Publication of JPWO2019224790A5 publication Critical patent/JPWO2019224790A5/ja
Priority to JP2023191446A priority Critical patent/JP7653092B2/ja
Application granted granted Critical
Publication of JP7384903B2 publication Critical patent/JP7384903B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021515306A 2018-05-24 2019-05-24 フルベストラントのプロドラッグ Active JP7384903B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023191446A JP7653092B2 (ja) 2018-05-24 2023-11-09 フルベストラントのプロドラッグ

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201821019542 2018-05-24
IN201821019542 2018-05-24
IN201821047939 2018-12-18
IN201821047939 2018-12-18
PCT/IB2019/054315 WO2019224790A2 (en) 2018-05-24 2019-05-24 Prodrugs of fulvestrant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023191446A Division JP7653092B2 (ja) 2018-05-24 2023-11-09 フルベストラントのプロドラッグ

Publications (4)

Publication Number Publication Date
JP2021525278A JP2021525278A (ja) 2021-09-24
JP2021525278A5 true JP2021525278A5 (https=) 2022-06-13
JPWO2019224790A5 JPWO2019224790A5 (https=) 2022-06-13
JP7384903B2 JP7384903B2 (ja) 2023-11-21

Family

ID=68615936

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021515306A Active JP7384903B2 (ja) 2018-05-24 2019-05-24 フルベストラントのプロドラッグ
JP2023191446A Active JP7653092B2 (ja) 2018-05-24 2023-11-09 フルベストラントのプロドラッグ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023191446A Active JP7653092B2 (ja) 2018-05-24 2023-11-09 フルベストラントのプロドラッグ

Country Status (6)

Country Link
US (1) US20210253626A1 (https=)
EP (1) EP3801553B1 (https=)
JP (2) JP7384903B2 (https=)
AU (1) AU2019274815B2 (https=)
CA (1) CA3101421C (https=)
WO (1) WO2019224790A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7384903B2 (ja) * 2018-05-24 2023-11-21 ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー フルベストラントのプロドラッグ
EP4061376A4 (en) * 2019-11-24 2024-03-13 Kashiv Biosciences, LLC Prodrugs of fulvestrant
TW202146405A (zh) * 2020-02-25 2021-12-16 日商大日本住友製藥股份有限公司 Cdk9抑制劑前體藥物及內封其之脂質體
WO2022034587A1 (en) * 2020-08-10 2022-02-17 Tnik Therapeutics Ltd Traf2- AND Nck-INTERACTING KINASE (TNIK) INHIBITORS AND USES THEREOF
WO2023027032A1 (ja) * 2021-08-23 2023-03-02 住友ファーマ株式会社 自己分解型ｃｄｋ９阻害剤プロドラッグ及びそれを内封するリポソーム
AU2022377397A1 (en) * 2021-10-29 2024-06-13 Kashiv Biosciences, Llc Inectable pharmaceutical composition for treatment of breast cancer
CN117957238A (zh) * 2021-12-06 2024-04-30 江苏亚虹医药科技股份有限公司 氟维司群衍生物及其制备方法和医药用途
EP4444318A4 (en) * 2021-12-06 2026-01-28 Amneal Pharmaceuticals Llc COMPOUNDS FOR CANCER TREATMENT
CN119751533B (zh) * 2025-03-10 2026-01-13 山东大学 一种基于雌甾三烯结构的雌激素受体蛋白靶向降解嵌合体衍生物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
CA2909418A1 (en) * 2013-04-18 2014-10-23 Xi'an Libang Pharmaceutical Technology Co., Ltd. Ester derivative of 7-.alpha.-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)n onyl]-estra-1,3,5(10)-triene-3,17.beta.-diol having anticancer activity and preparation method thereof
CN103421069A (zh) 2013-05-23 2013-12-04 中国海洋大学 氟维司群磷酸酯衍生物及其制备方法和应用
US10112962B2 (en) 2014-07-02 2018-10-30 Xavier University Boron-based prodrug strategy for increased bioavailability and lower-dosage requirements for drug molecules containing at least one phenol (or aromatic hydroxyl) group
WO2019050850A1 (en) * 2017-09-05 2019-03-14 Primetime Life Sciences, Llc BIGUANIDINE DERIVATIVES OF THERAPEUTIC AGENTS, AND PREPARATION METHODS AND METHODS OF USING SAME
CN108159055A (zh) * 2018-01-04 2018-06-15 西安力邦医药科技有限责任公司 治疗乳腺癌的长效递药系统、其制备方法及应用
JP7384903B2 (ja) * 2018-05-24 2023-11-21 ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー フルベストラントのプロドラッグ

Similar Documents

Publication Publication Date Title
JP2021525278A5 (https=)
US11040035B2 (en) 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
JP2021011495A5 (https=)
JP6419155B2 (ja) Ｎ−フェニル−カルボキサミド誘導体およびｂ型肝炎を治療するための医薬品としてのその使用
JP2020532506A5 (https=)
JP2019518766A5 (https=)
JP2021534124A5 (https=)
JP2020515610A5 (https=)
JP2016537358A5 (https=)
JP2020502092A5 (https=)
JP2017537158A5 (https=)
JP2005526723A5 (https=)
RU2003115490A (ru) Амидные производные в качестве антагонистов nmda рецептора
JP2014506599A5 (https=)
JP2011509309A5 (https=)
JP2008505157A5 (https=)
JP2012518634A5 (https=)
JP2021535213A5 (https=)
JP7112755B2 (ja) Ｊａｋ酵素阻害剤及びその製造方法と用途
JP2002529465A5 (https=)
RU2005140379A (ru) Замещенные циклопропильной группой оксазолидиноновые антибиотики и их производные
RU2007147344A (ru) Новые производные 2-азетидинона для лечения гиперлипидемических заболеваний
JP2007514691A5 (https=)
EP2664620A3 (en) N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline form and processes
JP2007531766A5 (https=)